Accurate Hormone Testing - Module 1: The Importance of Hormone Measurements and Assay Standardization

Welcome to Accurate Hormone Testing, a new 4-part course from Endocrine Society and the Partnership for the Accurate Testing of Hormones (PATH) exploring the endocrinologist’s main tool, hormone assays. This course, funded by the Centers for Disease Control (CDC), seeks to educate fellows and endocrinologists on the importance of, and methods to ensure, accurate hormone testing.

This activity contains the first module in this series, The Importance of Hormone Measurements and Assay Standardization, with Alvin M. Matsumoto, MD. Eligible for 1.5 AMA PRA Category 1 Credits, this module features a didactic presentation followed by case-based questions. Click Start to enroll in the course and start learning about hormone standardization.

Interested in the rest of the series? View our program for anticipated release dates.

Target Audience

This program will be of substantial interest to endocrinology fellows, early-career providers, and endocrinologists interested in learning more about hormone standardization.

Learning Objectives

By the end of this module, learners will be able to:

  • Understand the variability of hormone measurements and the importance of accurate, comparable, and reliable measurements
  • Utilize hormone measurements to diagnose patients
  • Apply common methodologies for standardization
  • Synthesize the effect of standardization on testing and the impact that varying reference ranges and guidelines have on testing.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Clinical researcher
Educator/Teacher
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation
Course opens: 
12/04/2020
Course expires: 
12/31/2022
Parent activity set: 
Rating: 
0

We will be releasing the other modules in this series each quarter:

Module 1 – Released December 2020

Module 2 – Released April 2021

Module 3 – Released August 2021

Module 4 – Released December 2021

Faculty

Alvin M. Matsumoto, MD
University of Washington School of Medicine
VA Puget Sound Health Care System

Peer-Reviewers

Hubert Vesper, PhD
CDC/DDNID/NCEH/DLS

Robert Fitzgerald, MD
University of California, San Diego

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Alvin M. Matsumoto, MD:
AbbVie, GlaxoSmithKline – Research Support; UpToDate – Editor; United States Anti-Doping Agency – TUE Committee; Partnership for Clean Competition – Scientific Advisory Board; American Society for Bone and Mineral Research – Partnership for the Accurate Testing of Hormones (PATH) Co-Chair.

The following peer reviewers reported relevant financial relationships:
Robert Fitzgerald, MD:
Roche Diagnostics – Consulting Fee; Roche Diagnostics and Waters Corporation – Institutional Support to Fellowship Program Dr. Fitzgerald directs.

The following peer reviewers reported no relevant financial relationships: Hubert Vesper, PhD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This educational activity is supported by an independent medical educational grant from the Centers for Disease Control (CDC).

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and the Partnership for the Accurate Testing of Hormones (PATH). The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.

The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Available Credit

  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation

Please click Start below to begin this module.

Prerequisites

Required courses: